Cambridge Antibody Technology has announced two appointments and one promotion to the key management position of vice president (VP).
Dr Patrick Round joins the company as VP, Development, responsible for CAT's product development activities. Prior to joining CAT, Patrick was director of Development at Celltech Research & Development, Slough, UK and was responsible for development activities in preclinical, Clinical, Regulatory, Biometrics, Project Management, Pharmacovigilance and Quality Assurance. Patrick has also held positions at Glaxo Wellcome, Novo Nordisk A/S, Denmark and Novo Nordisk Pharmaceuticals, UK. He is a qualified anaesthetist and graduated in Medicine from Charing Cross Hospital Medical School, London.
Dr Neil Stutchbury joins CAT as VP, Informatics and Information Technology and will lead the delivery of an Informatics and Information Techonlogy strategy to support CAT's development. Previously, Neil was VP, Research and Development Information Systems for AstraZeneca Pharmaceuticals where he was responsible for delivering the Information Systems and Information Technology strategy, and the integration of the computing systems post-merger at its seven Research and Development sites. Prior to the merger, he held various positions at Zeneca and ICI, having joined the Company in 1983. Neil has a First Class Honours degree in Chemistry and a doctorate of Philosophy in Theoretical Chemistry, both from the University of Oxford.
Dr Diane Wilcock is promoted to the position of VP, Intellectual Property, responsible for managing the Company's patent portfolio and patent strategy. Diane joined CAT in June 1999 and, prior to her promotion, held the position of Director of Intellectual Property. Before joining CAT, Diane worked in technology transfer for Imperial Cancer Research Technology, the commercial arm of the Imperial Cancer Research Fund and undertook post-doctoral research in molecular virology at the University of Oxford. Diane has a degree in Natural Sciences from the University of Cambridge, a doctorate in Biochemistry from the University of London, and an MBA from Imperial College, London.
Peter Chambré, chief executive officer at CAT, commented "CAT's evolution as a biopharmaceutical company is underpinned by the knowledge and expertise of our exceptional staff. These key appointments are new positions set to strengthen and broaden the experience of our team and support CAT's development. We are delighted to welcome Patrick and Neil, and also reward Diane's contribution and expertise in the field of Intellectual Property."